Responses
Friday 07 October 2022 from 13:00 to 14:10
Po.6 E- poster session 6: management and recommendations, old and new therapies/biologics
PO.6.126 Anti-rituximab antibodies demonstrate neutralising capacity, associate with lower circulating drug levels and early relapse in patients undergoing treatment for systemic lupus erythematosus
Compose a Response to This Article
Other responses
No responses have been published for this article.